A Growing CDMO

I hope you know that there’s a fruity new brand in town: Bramble Bio! We launched the name in January this year and it represents our contract development and manufacturing organization (CDMO), previously called Famicord Cell and Gene Manufacturing. Since then, we have a flashy new website (bramble.bio) and have implemented many sales and marketing initiatives as we increase our market presence and grow our revenues.

We’re delighted to announce the recent signing of two major projects: one with an existing customer and one new:

BIONCaRT

We’ve been working with BIONCaRT for many years and have already developed the manufacturing process for their lead cell therapy, MesemCart, based on WJ-MSCs. It’s the first allogeneic stem cell therapy for the treatment of knee cartilage damage in Europe. We’re manufacturing for their clinical Phase I/IIa right now, with patients expected to be treated towards the end of this year. We partnered with the prestigious Fraunhofer Institute, who are doing the final release into Germany.

André Gerth, Founder and CEO at BIONCaRT said “we are delighted to be partnering with Bramble Bio and Fraunhofer IZI, two leading organizations in the cell therapy manufacturing space. This collaboration brings the potential of offering patients with debilitating knee cartilage damage a much-needed regenerative treatment option.”

Keli Therapeutics

We also welcome Keli Therapeutics, a Lithuanian biotech with 6 cell therapy products in their pipeline. We’ll be transferring in the manufacturing process for their lead project for post-cardiac surgery acute kidney injury – that’s the most common post-cardiac surgery complication. It’s based on placental stromal cells and will enter a clinical Phase Ib/II trial next year. Their CEO and CSO visited us in August for technical discussions and a laboratory tour. Their CEO, Justinas Maciulaitis said he was “delighted to be partnering with us and really looking forward to getting the project started”.

We also currently have projects with clients in Spain, Portugal, Sweden, US and Poland, thanks to a strong performance by our operational and sales teams. More to follow as we add more clients and revenue to this growing business!